Compare Harmony Gold Mining Co. (HMY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Sanofi SA — how do they compare? Harmony Gold Mining Co. trades at $15.88 (market cap $9.48B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 11.1× Harmony Gold Mining Co.'s market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| HMY | SNY | |
|---|---|---|
Market Cap | $9.48B | $104.85B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $52.34 |
52-Week Low | $12.61 | $41.33 |
Enterprise Value | $9.82B | $121.38B |
Dividend Yield | 2.66% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $15.325, up 4.61% today, but technical indicators signal a bearish trend with key resistance at $15. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, yet recent earnings missed expectations. Cash flow from operations improved to $15.65B in 2024, though 2025 projections show a net cash outflow. Analyst sentiment is mixed, with 70% hold ratings, reflecting caution amid gold price volatility and Fed rate hike concerns.
The outlook for HMY hinges on gold and copper price stability, with operational execution critical. Investment opportunities include a low P/E of 9.17 and a 4.06% dividend yield, but risks involve earnings misses, rising costs, and macroeconomic pressures. Investors should weigh strong profitability against sector headwinds and analyst skepticism.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
